Journal of Pharmacy Technology: Official Publication of the Association of Pharmacy Technicians January-December 2006: Vol 22 Index

1.7 MB·English

INDEX, the journal of Pharmacy Technology
VOLUME Twenty-two — JANUARY THROUGH DECEMBER 2006
January/February Pages 1-76 July/August Pages 205-248
March/April Pages 77-140 September/October Pages 249-316
May/June Pages 141-204 November/December Pages 317-386
Antiresorptive therapies, use in Crohn’s dis- B-Blockers, impact of dose change in heart
A-C ease (A), 9 failure (A), 79
Arbo, Trudy C (coauthor), see Tejani, Aaron Bislew, Heather D (author), book review, 242
Abarca, Jacob (coauthor), see Murphy, John M, 168 Bisphosphonates, with raloxifene, osteoporo-
E, 155 Armour, Carol L (coauthor), see Krass, Ines, 3 sis treatment (A), 215
Abatacept, vs methotrexate, effect in rheuma- Armstrong, Edward P (coauthor), see Mur- Blood pressure, attainment of goal using JNC
toid arthritis (TT), 229 phy, John E, 155 7 guidelines (A), 86
Abatacept: A Novel Agent for Rheumatoid Arunkumar, Punitha (coauthor), see Kishel, Blouin, Julie (author), Implementation of an
Arthritis (A), 336 Joseph J, 48 Algorithm for Intravenous Pantoprazole:
Abbreviations, reduction of use of restricted Aspirin, prevention of aminoglycoside-in- Impact on Prescription Compliance in Que-
abbreviations (A), 332 duced hearing loss (TT), 181, with ACE in- bec University Hospitals (A), 261
Acetaminophen, liver toxicity with overuse hibitors and statins, reduced severity of
Books received, 70, 134, 199, 243, 311, 374
(WN), 232 stroke (TT), 182
Brouse, Sara D (author), Impact of f-Blocker
Adherence, diabetes regimens (TT), 54; effect Assessing Adherence to an Intravenous Pan- Dosage Changes During Heart Failure Ex-
of drug cost (PF), 61; effectiveness of long- toprazole Guideline (A), 15
acerbation (A), 79
lasting drug formulations (WN), 57; faxed Association of Cardiac Drugs with Depres-
Budesonide, concomitant therapy effective in
alerts to physicians (WN), 184; HIV pill bur- sion after Acute Coronary Syndrome (A), chronic obstructive pulmonary disease
den (TT), 55; pantoprazole guidelines (A), 319
(TT), 228; use in Crohn's disease (TT), 181
15; ulcerative colitis drugs, not affected by Asthma, increased risk in teens who smoke
Burkiewicz, Jill S (author), Educational Inter-
formulation or regimen (TT), 353 (WN), 362; underuse of therapy (WN), 361
vention to Reduce Frequency of Use of Re-
Adigun, Adegboyega Q (author), An Audit Atazanavir sulfate, with or without ritonavir,
stricted Abbreviations in a Community
of Lipid Management in Patients with Dia- in treatment-naive patients (TT), 116
Health Center (A), 332
betes in an Academic Internal Medicine Atomoxetine, effective in attention deficit / hy-
Burny, Ilyas (author), Pattern of Medication
Practice (A), 207 peractivity disorder and reading disorders
Use and Errors in a Tertiary Care Children’s
Adverse drug reactions, electronic reporting (TT), 357
Hospital Intensive Care Unit (A), 326
(PF), 61; incidence in elderly (WN), 300 Atorvastatin, with torcetrapib, increased
Calcium-channel blocker, vs angiotensin-
Aiken, Cheryl A (coauthor), see Kennedy, HDL-C (TT), 115
converting enzyme inhibitor in chronic sta-
Amanda G, 42 Atripla, FDA approval (FL), 366
Aminoglycosides, aspirin use in prevention Audit of Lipid Management in Patients with ble angina (A), 271
of hearing loss (TT), 181 Diabetes in an Academic Internal Calendar of Events, 68, 129, 194, 240, 307, 369
Anaphylactic Shock to Oxaliplatin in the Medicine Practice (A), 207 Cancer, lung, treatment in smokers vs non-
Adjuvant Context (A), 221 Ayesu, Linda W (coauthor), see Willmore, smokers (WN), 186
Anastrozole, compared with tamoxifen, Catherine B, 32 Capurso, Kevin A (author), Barriers to Imple-
breast cancer (TT), 56 Azithromycin, increased risk of reinfection menting a Pharmacist-Run Immunization
Angiotensin-converting enzyme inhibitors, (WN), 301 Service, as Perceived by Pharmacists, in a
with aspirin and statins, reduced severity of Bachmann, Kenneth A (coauthor), see Lewis, Community Pharmacy Chain (A), 91
stroke (TT), 182; versus calcium-channel Jeffrey D, 22 Carpenter, Jane F (author), Stability of Omep-
blocker in chronic stable angina (A), 271 Barriers to Implementing a Pharmacist-Run razole Sodium and Pantoprazole Sodium
Antibiotics, inappropriate use in pneumonia Immunization Service, as Perceived by Diluted for Intravenous Infusion (A), 95
(WN), 231; mistaken beliefs about effective- Pharmacists, in a Community Pharmacy Carvedilol, on hospital discharge, effect on
ness (WN), 232 Chain (A), 91 survival (TT), 116
Antipsychotics, increased use in children BAY 59-7939, prevention of thromboembolic Cerrito, John C (coauthor), see Cerrito, Patri-
(WN), 187 events (TT), 53 cia B, 143
WWW. )JPHARMTECHNOL.COM Novemser/Decemser 2006 @ Vow.me 22 w J PHARMTeECHNOL§ 381
Cerrito, Patricia B (author), Use of Pharmacy Dapsone, stability of oral suspension (CF), 130 Ferrone, Marcus (coauthor), see Hughes,
Database to Investigate Patterns of Physi- Databases, ASHP and Script IQ link (PF), 61; Caren L, 281
cian Practice as Related to Patient Out- pharmacy, investigate physician practice Fish, Douglas N (coauthor), see MacLaren,
comes (A), 143 patterns (A), 143; Pharmacy Technician Cer- Robert, 15
Charneski, Lisa (coauthor), see Sheth, Neha tification Board aid after Hurricane Katrina Flecainide, compounding of oral suspension
U, 336 (PF), 62 (CF), 241
Cheng, Christine M (author), Lanthanum Depression, association with use of cardiac Florida, evaluation of technicians practice
Carbonate Treatment of Hyperphos- drugs (A), 319 statutes (FS), 63
phatemia in End-Stage Renal Disease (A), 99 Désaulniers, Pierre-Louis (coauthor), see Flucytosine, compounding of oral suspension
Chloroquine, oral suspension compounding Blouin, Julie, 261 (CF), 241
(CF), 69 Dexamethasone, stability of oral suspension Fluticasone, with salmeterol, effective in asth-
Chronic obstructive pulmonary disease, lack (CF), 130 ma (TT), 228
of patient understanding (WN), 362; under- Diabetes, adherence to treatment regimens Fondaparinux, risk of venous thromboem-
use of therapy (WN), 361 (TT), 54; lipid management (A), 207; pa- bolism (TT), 115
Chronic Stable Angina: Angiotensin-Con- tients unaware of association with stroke Ford, Stephen M (author), book review, 371
verting Enzyme Inhibitor Therapy and/or (WN), 185
Calcium-Channel Blocker Therapy— Diabetes, type 2, pharmacist’s role in care (A),
When Is It Indicated? (A), 271 3; vildagliptin (LAF 237) treatment (A), 105 G-l
Clopidogrel, effect on peripheral arterial dis- Diltiazem, compounding of oral suspension
ease (WN), 57; risk of nonadherence (WN), (CF), 195 Gabapentin, compounding of oral suspen-
121 Dipyridamole, compounding of oral suspen- sion (CF), 308
Clostridium difficile, increased incidence sion (CF), 195 Ganciclovir, compounding of oral suspension
(WN), 300 Donato, Anthony A (coauthor), see Adigun, (CF), 308
Cocaine, use linked to Parkinson's disease Adegboyega Q, 207 Gaynor, Ken N (coauthor), see Burny, Ilyas,
(WN), 59; ondansetron use in dependence Dragomir, Alice (coauthor), see Blouin, Julie, 326
(TT), 180 261 Geriatric pharmacy, medication management
Colucci, Vincent J (author), Potential Contri- Drug abuse, prescription drugs, countering needed to lower risk of fractures (WN), 360;
bution of Long-Term Rofecoxib in a Patient efforts (WN), 299 record number of pharmacist specialty cer-
with Cardiogenic Syncope and Ischemic Drug information, FDA management of safe- tifications (PF), 127
Stroke (A), 174 ty issues (FL), 189 Glatiramer, with mitoxantrone, effective in
Combination of Methylphenidate, Venlafax- Drug interactions, role of cytochrome P450 multiple sclerosis (TT), 227
ine, and Escitalopram Resulting in Sero- enzymes (A), 22; role of technicians in man- Glitazars, failing clinical trials (WN), 299
tonin Syndrome (A), 110
aging alerts (A), 155 Glucose monitoring, accurate coding of me-
Combining Bisphosphonates with Ralox- Duloxetine, high-dose, compared with low- ters important (WN), 359; free monitoring
ifene to Treat Osteoporosis: A Review of dose escitalopram (TT), 56 systems (WN), 299; skin biomarker more
the Evidence (A), 215
Dunn, Susan (coauthor), see Corser, William, accurate than fasting plasma glucose and
Compliance with the JNC 7 Guidelines and
319 AIC (WN), 359
Blood Pressure Attainment in an Inner-
City Tertiary Care Hospital (A), 86 Dusci, Leon J (coauthor), see Carpenter, Jane Grapefruit juice, substance responsible for in-
E95 teractions identified (WN), 185
Compounding, ruling on legality (PF), 305
Eczema, difference from dry skin (WN), 298 Grizzle, Amy J (coauthor), see Murphy, John
Controlled substances, Omnice!l SecureVault
Eczema/atopic dermatitis, patient education E, 155
available (WN), 232
booklet (WN), 121 Growth hormone, practice guidelines avail-
Cornell, Susan (author), Vildagliptin (LAF
237): A Dipeptidy! Peptidase IV Inhibitor Edick, Cathleen M (coauthor), see Smith, able (WN), 231
for the Treatment of Type 2 Diabetes Melli- Curtis L, 161 Hafezi, Shideh (coauthor), see Brouse, Sara D,
Educational Intervention to Reduce Fre- 79
tus (A), 105
Corser, William (author), Association of Car- quency of Use of Restricted Abbreviations Hanak, Michael (coauthor), see Corser,
diac Drugs with Depression after Acute in a Community Health Center (A), 332 William, 319
Coronary Syndrome (A), 319 Enoxaparin, safety vs unfractionated heparin Hassenplug, Karen L (coauthor), see
Corticosteroids, inhaled, effective in chronic (TT), 293 Burkiewicz, Jill S, 332
obstructive pulmonary disease (TT), 297; Entecavir, low resistance levels in nucleoside- Heart failure, impact of f-blocker dose
naive chronic hepatitis B patients (TT), 355 change (A), 79
withdrawal, lowers toxic effects of antirejec-
Epinephrine Versus Vasopressin in Adult Heparin, unfractionated, safety vs enoxa-
tion drugs (TT), 229
Counterfeit drugs, dangers (PF), 236; tools of Cardiac Arrest: Role of Agonal Respira- parin (TT), 293
Partnership for Safe Medicines (PF), 62; tions and Patient Age (O), 251 Hepatitis C, shorter therapy course effective
Web site and podcasts instituted (PF), 368; Epoetin alfa, costs less than darbepoetin alfa (TT), 181
Web site available for consumer education (TT), 354 Herbal products, reasons users inform /do not
(WN), 232; World Health Organization pre- Escitalopram, low-dose, compared with high- inform physicians (A), 148
pares anti-counterfeiting plan (WN), 360 dose duloxetine (TT), 56; with venlafaxine Herman, Ronald A (author), book review, 132
Crohn’s disease, risk for osteoporosis (A), 9 and methylphenidate, serotonin syndrome Hilas, Olga (coauthor), see Sheth, Neha U, 336
Curry, Clarence E Jr (author), book review 131 (A), 110 Hispanics, increased drug development for
Curry, Colleen M (author), book review, 70 Estradiol, transdermal gel, NDA submitted the population (WN), 300
Cyr, Monica (author), book review, 371 (WN), 123 Holiday-Goodman, Monica (coauthor), see
Cytochrome P450 Enzymes and Drug-Drug Estrogen, heart protection in younger women Shah, Bupendra K, 148
Interactions: An Update on the Superfami- (TT), 120 Holmes-Rovner, Margaret (coauthor), see
ly (A), 22 Etanercept, treatment of elevated C-reactive Corser, William, 319
protein (WN), 184 Hughes, Caren L (author), Sorafenib for the
D-F Exceeding Expectations for Educational Ex- Treatment of Renal Cell Carcinoma (A), 281
cellence: 2006 PTEC Annual Meeting re- Hydroxychloroquine, oral suspension com-
port (PTEC News), 289 pounding (CF), 370
Dagenais, Pierre (coauthor), see Makhzoum, Exubera, effective in respiratory compromise Hyperlipidemia, physician acceptance of
Josette, 9 (TT), 295 treatment program (A), 211
Dantrolene, oral suspension compounding Febuxostat, a Novel, Non-Purine Xanthine Hypertriglyceridemia, people unaware of
(CF), 69 Oxidase Inhibitor (A), 342 risks (WN), 298
382 J PHarm TecHNot @ Vowume 22 Novemser/Decemser 2006 WWWJPHARMTECHNOL.COM
Ibandronate sodium, improved adherence Lizer, Mitsi H (author), Combination of Meth- Nesiritide, benefits in coronary artery bypass
(TT), 296; women’s preference (WN), 122 ylphenidate, Venlafaxine, and Escitalopram graft (TT), 293
Ilett, Kenneth F (coauthor), see Carpenter, Resulting in Serotonin Syndrome (A), 110 Neurology, pharmacotherapy clinic (A), 254
Jane F, 95 Lloyd, Benjamin J (coauthor), see Adigun, New Publications, Bioterrorism Preparedness:
Illinois, technician education on poison con- Adegboyega Q, 207 Medicine, Public Health, Policy, 371; Complete
trol (FS), 193 Lubiprostone, effective within 2448 hours Math Review for the Pharmacy Techneian, 2nd
Immunizations, pharmacy-run service, barri- (TT), 353 edition, 70; Drug-Induced Diseases: Preven-
ers (A), 91 Lukasiewicz, Ronald H (author), book re- tion, Detection, and Management, 242; Essen-
Impact of (-Blocker Dosage Changes During view, 373 tials of Clinical Psychopharmacology, 2nd edi-
Heart Failure Exacerbation (A), 79 Lutein, beneficial for skin (WN), 298 tion, 371; Ethics and the Pharmaceutical
Implementation of an Algorithm for Intra- LY517717, prevention of thromboembolic Industry, 310; Mosby's Drug Consult 2005
venous Pantoprazole: Impact on Prescrip- events (TT), 53 Handheld Software on CD-ROM (Mosby’s Rx),
tion Compliance in Quebec University 132; Nonprescription Product Therapeutics,
Hospitals (A), 261 2nd edition, 196; Pharmacologfyo r Techni-
Infection, hospital-acquired, effect on con- M-N cians, 3rd edition, 197; Preparing the Pharma-
sumer’s hospital choice (WN), 58 cy for Continuous Compliance with Joint Com-
Infliximab, long-term treatment of ulcerative MacLaren, Robert (author), Assessing Adher- mission Standards, 6th edition, 372;
colitis (TT), 54 ence to an Intravenous Pantoprazole Remington: The Science and Practice of Phar-
Influenza, benefits of vaccination (FL), 302; Guideline (A), 15 macy, 21st edition, 133; Symptoms in the
preparation for season (FL), 234 Makhzoum, Josette (author), Risk for Osteo- Pharmacy: A Guide to the Management of
Insect stings, low incidence of hospital treat- porosis and Antiresorptive Therapies in Pa- Common Illness, 5th edition, 131; Taking Your
ment (WN), 184 tients with Crohn's Disease (A), 9 Medicine: A Guide to Medication Regimens and
Insulin pen, improves clinical outcomes, re- Makhzoum, Sylvie (coauthor), see Compliancfeo r Patients and Caregivers, 242;
duces medical costs (TT), 352 Makhzoum, Josette, 9 The Top 100 Drug Interactions: A Guide to Pa-
Itraconazole, oral suspension compounding Malaria, safety of mefloquine prophylaxis tient Management, 2006 edition, 309; Under-
(CF), 370 (A), 32; test kit available (WN), 186 standing Pharmacy Reimbursement, 373
Malone, Daniel C (coauthor), see Murphy, Ng Van Tze, Christina (author), Anaphylactic
John E, 155 Shock to Oxaliplatin in the Adjuvant Con-
J-L Marrs, Joel C (author), Chronic Stable Angi- text (A), 221
na: Angiotensin-Converting Enzyme In- Nuclear pharmacy, board certification avail-
Jobin, Gilles (coauthor), see Makhzoum, hibitor Therapy and / or Calcium-Channel able (PF), 127
Josette, 9 Blocker Therapy—When Is It Indicated?
journal of Pharmacy Technology, author (A), 271 O-R
guidelines, ifc-] / F, ife-M/ A, ifc-M/J, ifc- Masters, Kelly P (coauthor), see Lizer, Mitsi
}/ A; ife-S/O; ife-N /D; subscription order H, 110
form, 52, 114,179, 226, 292, 349 McInman, Adrian D (coauthor), see Krass, Obesity, effect on intramuscular injections
(WN), 58
Jung, Rose (coauthor), see MacLaren, Robert, Ines, 3
15 McNulty, Margaret A (coauthor), see Carpen- Obritsch, Marilee D (coauthor), see MacLaren,
Robert, 15
Keeping Score on Psychiatric Drug Effects: ter, Jane F, 95
Is Mefloquine Safe for Malaria Chemo- Medicare, online guide available (PF), 368 Olomu, Ade (coauthor), see Corser, William,
319
prophylaxis? (A), 32 Medication errors, electronic reporting (PF),
Omeprazole, stability (A), 95
Kelley, Dwight B (author), book review, 309 61; patterns in pediatric intensive care unit Ondansetron, underdiagnosed in men (WN),
Kennedy, Amanda G (author), A Survey of (A), 326; technicians’ experiences (A), 42
186; use in cocaine dependence (TT), 180
the Medication Error Experiences of Phar- Medication-related problems, effect of phar-
Onychomycosis, contagious (WN), 300
macy Technicians (A), 42 macist-patient interaction (PF), 190
Opioids, higher incidence of overdose vs co-
Kim, Karissa Y (author), Febuxostat, a Novel, Medication safety, physician concerns (PF),
caine or heroin (WN), 233
Non-Purine Xanthine Oxidase Inhibitor (A), 236
Oral contraceptive, loss of sexual desire
342 Mefloquine, safety in prophylaxis (A), 32
(WN), 123
Kishel, Joseph J (author), Two Approaches to Metformin, with sitagliptin, effective in re- Orlistat, effect in control of glucose levels
Treatment of Complicated Candida glabrata duction of glycosylated hemoglobin (TT), (TT), 294; low doses effective (TT), 295; re-
Urinary Tract Infection in Renal Failure (A), 295 duction in LDL-C independent of weight
48 Methotrexate, vs abatacept, effect in rheuma-
loss (TT), 351
Krass, Ines (author), The Pharmacist’s Role in toid arthritis (TT), 229 Osteoporosis, increasing incidence (WN), 302;
Continuity of Care in Type 2 Diabetes: An Migraines, management (FL), 124 prediction of fracture risk (WN), 301; risk in
Evaluation of a Model (A), 3 Miller, Brian M (author), Combining Bisphos- Crohn’s disease (A), 9
Krueger, Courtney (author), book review, 242 phonates with Raloxifene to Treat Osteo- Otitis media, vaccine in development (WN),
Labeling, uniform guidelines approved by In- porosis: A Review of the Evidence (A), 215 302
ternational Academy of Compounding Mitoxantrone, with glatiramer, effective in Oxaliplatin, associated with anaphylactic
Pharmacists (PF), 126 multiple sclerosis (TT), 227 shock (A), 221
Lanthanum, reduced pill burden (TT), 182 Mohr, Mary E (author), book review, 133 Oxytrex, treatment of severe chronic pain
Lanthanum Carbonate Treatment of Hyper- Mometasone, effective for nasal polyps (TT), (TT), 119
phosphatemia in End-Stage Renal Disease 53 Pain, high incidence in US (WN), 361; man-
(A), 99 Murphy, John E (author), The Role of Techni- agement, pharmacist CE monograph avail-
Levine, Marc (author), book review, 310 cians in Managing Computerized able (PF), 127
Lewis, Jeffrey D (author), Cytochrome P450 Drug-Drug Interaction Alerts in Communi- Pain medication, use linked to farmer's in-
Enzymes and Drug-Drug Interactions: An ty Pharmacies and the Relationship to Phar- juries (WN), 230
Update on the Superfamily (A), 22 macist Managers’ Attitudes (A), 155 Paliperidone ER, treatment of schizophrenia
Lexi-Comp, change-log system available for Myocardial infarction, Web site available for (TT), 56
Lexi-CONNECT (PF), 127 patient education (WN), 185 Palmieri, James (author), Physician Accep-
Lieh-Lai, Mary W (coauthor), see Burny, Naproxen, with sumatriptin, effective in mi- tance of a Hyperlipidemia Program's
Ilyas, 326 graine (TT), 227, (TT), 296 Adaptation of the National Cholesterol Ed-
Lively, Buford T (coauthor), see Shah, Bu- Needle sticks, association with anxiety and ucation Program’s Adult Treatment Panel
pendra K, 148 stress (WN), 361 Ill Update (A), 211
WWW. JPHARMTECHNOL.COM Novemser/Decemser 2006 ws Vowme22 w@ J PHARMTECHNOL 383
Pantoprazole, adherence to guidelines (A), 15; Reed, Pamela (coauthor), see Swims, Melanie Smith, Curtis L (author), Smoking Cessation
prescription compliance with algorithm P, 254 Therapy in Pregnancy (A), 161
(A), 261; stability (A), 95 Rehfeld, Rick A (coauthor), see Murphy, Smoking, pharmacists trained for patient ed-
Parenteral nutrition, ursodeoxycholic acid for John E, 155 ucation (PF), 192
treatment of cholestatis (A), 168 Renal cell carcinoma, sorafenib treatment (A), Smoking Cessation Therapy in Pregnancy (A),
Patel, Sheel M (coauthor), see Miller, Brian 281 161
M, 215 Renal failure, lanthanum carbonate treatment Sodium oxybate, treatment of fibromylagia
Patient-reported outcomes, importance in (A), 99; treatment of urinary tract infection (TT), 118
treatment (FL), 364 (A), 48 Sokos, Denise R (coauthor), see Miller, Brian
Pattern of Medication Use and Errors in a Restless legs syndrome, treatment (FL), 188 M, 215
Tertiary Care Children’s Hospital Inten- Rheumatoid arthritis, abatacept treatment Solifenacin, vs tolterodine, overactive bladder
sive Care Unit (A), 326 (A), 336 (TT), 297
Peginterferon alfa-2a, with ribavirin, increased Ribavirin, with peginterferon alfa-2a, in- Sorafenib for the Treatment of Renal Cell
chance of cure in hepatitis C (TT), 356 creased chance of cure in hepatitis C (TT), Carcinoma (A), 281
Pegylated interferon, with valopicitabine, vi- 356 Stability of Omeprazole Sodium and Panto-
ral suppression in hepatitis C (TT), 55 Rios, Joanne M (author), book review, 197 prazole Sodium Diluted for Intravenous
Perreault, Sylvie (coauthor), see Blouin, Julie, Risedronate, treatment of male osteoporosis Infusion (A), 95
261; (coauthor), see Makhzoum, Josette, 9 (TT), 183 Statins, control growth of abdominal aortic
PharmaCE, order form, 72, 136, 203, 247, 315, Risk for Osteoporosis and Antiresorptive aneurysms (WN), 230; plus aspirin and
378; test, 73, 137, 201, 245, 313, 375 Therapies in Patients with Crohn’s Dis- ACE inhibitors, reduced severity of stroke
Pharmacist’s Role in Continuity of Care in ease (A), 9 (TT) 182; reduced morbidity and mortality
Type 2 Diabetes: An Evaluation of a Mod- Ritonavir, with atazanavir sulfate, in treat- in chronic heart failure (TT), 352; underuse
el (A), 3 ment-naive patients (TT), 116 in at-risk patients (WN), 121
Pharmacotherapy Clinic in a Neurologic Rivard, Erin K (coauthor), see Smith, Curtis Stommel, Manfred (coauthor), see Corser,
Practice (A), 254 L, 161 William, 319
Pharmacy Access Improvement Act, pharma- Rivey, Michael P (coauthor), see Colucci, Stuhan, Mary Ann (author), book review, 196;
cy support (PF), 190 Vincent J, 174 (author), Exceeding Expectations for Educa-
Pharmacy education, increased enrollment Rofecoxib, potential association with syncope tional Excellence: 2006 PTEC Annual Meet-
(PF), 304 (A), 174 ing Report (PTEC News), 289
Pharmacy practice, patient trust (PF), 191; Role of Technicians in Managing Computer-
Sugar, use as analgesic (WN), 59
physicians’ critique uninformed (PF), 191 ized Drug-Drug Interaction Alerts in
Sumatriptin, with naproxen, effective in mi-
Pharmacy Technician Certification Board, Community Pharmacies and the Relation-
graine (TT), 227, (TT), 296
practice analysis conducted (PF), 190 ship to Pharmacist Managers’ Attitudes
Survey of the Medication Error Experiences
Pharmacy Technician Educators Council, (A), 155 of Pharmacy Technicians (A), 42
2006 annual meeting report (PTEC News), Rosacea, associated with physical discomfort
Swims, Melanie P (author), A Pharmacother-
289 (WN), 122 apy Clinic in a Neurologic Practice (A), 254
Pharmacy technicians, medication error expe- Rosiglitazone, reduced risk of type 2 diabetes
Tamoxifen, compared with anastrozole,
riences (A), 42; practice in Mississippi (FS), (TT), 294
breast cancer (TT), 56; prophylaxis not ben-
238; role in managing drug—drug interac- Rosuvastatin, effective in hypercholes-
tion alerts (A), 155; supervisory roles (FS), terolemia (TT), 180; regression of atheroma eficial in most women (TT), 228
Tan, Winston W (coauthor), see Hughes,
238 (TT), 180
Physician Acceptance of a Hyperlipidemia Rottenberg, Eric M (author), Epinephrine Caren L, 281
Program’s Adaptation of the National Versus Vasopressin in Adult Cardiac Arrest: Taylor, Susan J (coauthor), see Krass, Ines, 3
Cholesterol Education Program’s Adult Role of Agonal Respirations and Patient Tejani, Aaron M (author), Ursodeoxycholic
Treatment Panel III Update (A), 211 Age (O), 251 Acid for the Treatment of Parenteral Nutri-
Pioglitazone, improved cardiovascular out- tion—Associated Cholestasis in Pediatric Pa-
comes in type 2 diabetes (TT) 294 tients (A), 168
Plakogiannis, Roda (author), Compliance S-Z Test Your Knowledge, answers, 76, 140, 204,
with the JNC 7 Guidelines and Blood Pres- 248, 316, 380; questions, 2, 78, 142, 206, 250,
sure Attainment in an Inner-City Tertiary Sakalis, Elias G (coauthor), see Plakogiannis, 318
Care Hospital (A), 86 Roda, 86 Thalidomide, treatment of multiple myeloma
Poitras, Pierre (coauthor), see Blouin, Julie, Salmeterol, with fluticasone, effective in asth- (TT), 182
261 ma (TT), 228 Thomas, Ronald L (coauthor), see Burny,
Potential Contribution of Long-Term Rofe- Sarnaik, Ashok P (coauthor), see Burny, Ilyas, 326
coxib in a Patient with Cardiogenic Syn- Ilyas, 326 Tinea pedis, contagious (WN), 300
cope and Ischemic Stroke (A), 174 Saseen, Joseph J (coauthor), see Marrs, Joel C, Tinidazole, compared with metronidazole,
Powers, Mary F (coauthor), see Capurso, 271 trichomoniasis (TT), 118
Kevin A, 91 Saw palmetto, treatment of benign prostatic Tipranavir, effect on HIV and CD4+ cells
Pramipexole, treatment of restless legs syn- hyperplasis (TT), 119 (TT), 117
drome (TT), 55 Shah, Bupendra K (author), Reasons Why Tolterodine, vs solifenacin, overactive bladder
Pramlintide, treatment of obesity (TT), 118 Herbal Users Do or Do Not Tell Their (TT), 297
Pregnancy, smoking cessation (A), 161 Physicians About Their Use: A Survey of Torcetrapib, with atorvastatin, increased
Prescribing, electronic, government funding Adult Ohio Residents (A), 148 HDL-C (TT), 115
(WN), 59 Sherman, Deborah S (coauthor), see Toremifene, treatment for adverse effects of
Prostate cancer, educational Web site avail- MacLaren, Robert, 15 androgen deprivation therapy (WN), 186
able (WN), 301 Sheth, Neha U (author), Abatacept: A Novel Tremblay, Lydjie (coauthor), see Blouin,
Race, African American, reducing cardiovas- Agent for Rheumatoid Arthritis (A), 336 Julie, 261
cular risk (WN), 58 Sirolimus, risk of cancer after kidney trans- Two Approaches to Treatment of Complicat-
Raloxifene, with bisphosphonates, osteoporo- plant (TT), 119 ed Candida glabrata Urinary Tract Infec-
sis treatment (A), 215 Sitagliptin, with metformin, effective in reduc- tion in Renal Failure (A), 48
Reasons Why Herbal Users Do or Do Not tion of glycosylated hemoglobin (TT), 295 Tyler, Linda S (author), book review, 372
Tell Their Physicians About Their Use: A Skrepnek, Grant H (coauthor), see Murphy, Urinary tract infection, treatment in renal fail-
Survey of Adult Ohio Residents (A), 148 John E, 155 ure (A), 48
384 = | PHarmTecHNot @ Voiwme22 Novemser/December 2006 WWW. JPHARMTECHNOL.COM
Ursodeoxycholic Acid for the Treatment of Willmore, Catherine B (author), Keeping
Parenteral Nutrition—Associated Cholesta- Score on Psychiatric Drug Effects: Is Meflo- Index Abbreviations
sis in Pediatric Patients (A), 168 quine Safe for Malaria Chemoprophylaxis?
Use of Pharmacy Database to Investigate (A), 32
Patterns of Physician Practice as Related to Woosley, Raymond L (coauthor), see Mur- A: Article
Patient Outcomes (A), 143 phy, John E, 155
E: Editorial
Valopicitabine, with pegylated interferon, vi- Yang, Zhou (coauthor), see Corser, William,
ral suppression in hepatitis C (TT), 55 319 FL:
Vardenafil, effective in men with cardiovascu- Zoledronic acid, fracture risk reduction (TT), GE:
lar risks (TT), 356 296
Varenicline tartrate, approved for use in to- ibe:
bacco cessation (FL), 235
Advertisers
Vasopressin, compared with epinephrine,
adult cardiac arrest (O), 251
Venlafaxine, with methylphenidate and esci- Christian Pharmacists Fellowship Interna-
talopram, serotonin syndrome (A), 110 tional, Christianity and Pharmacy, 253, 363
Venous thromboembolism, prevalence (TT), American Association of Pharmacy Techni-
54; prevention and treatment guidelines cians, convention 2006, 85; membership,
available (WN), 230 220, 269, 367
Vildagliptin (LAF 237): A Dipeptidyl Pepti- Harvey Whitney Books, The Annals of Phar-
dase IV Inhibitor for the Treatment of macotherapy For Our Patients, 341; Certifica-
Type 2 Diabetes Mellitus (A), 105 tion Review for Pharmacy Technicians, 7th edi-
Vincristine, need for improved safety prac- tion, ibe-] / F, ibe-M/ A; ibe-M/J, ibe-J/ A,
tices (WN), 122 ibe-S/O, ibe-N /D; Love Walks By Faith, 386; Statement of ownership, management, and monthly cir-
Vitamin D, effect on lung function (WN), 60 Medical Abbreviations, 12th edition, 233; 13th culation (6 issues, $168.00 annually) of the journal of Phar-
Washington, technician challenges in 2006 edition, 325; Pediatric Drug Formulations, 5th vmeayc y WhTietchnneoyl ogyB,o okpsub lCiocmatpiaonny .n o. Pu8b7l5i5s-h1e2r2 5.a ndO wneedirt,o r: Har-
(FS), 193 revision, 73, 306, 379; Pharmacoepidemiology: Harvey AK Whitney Jr. Headquarters of publisher, own-
White, Donald B (coauthor), see Shah, Bu- An Introduction, 3rd edition, 312, 350 er, and publication: 8044 Montgomery Road, PO Box
pendra K, 148 Pharmacy Technician Educators Council, 426%, Cincinnati, OH 45242. Known bondholders, mort-
Wigle, Patricia R (coauthor), see Kim, Karissa 2006 annual meeting, 135; membership, gages, and other security holders: none. Average no. of
Y, 342 225, 291, 358 copies of each issue from October 2005 to October 2006
and no. of copies of November /D ecember 2005 to
September /O ctober 2006 issue: a. total no. copies printed
(net press run) 600, 600; b. paid and/or requested circu-
lation (1) paid or requested mail subscriptions 391, 378; c.
total paid and /o r requested circulation 417, 408; d. free
distribution by mail 58, 58; e. total free distribution 58, 58;
f. total distribution 475, 466; g. copies not distributed 125,
134; h. Total 600, 600. No. of issues published annually: 6.
Date of filing 1 October 2006. Signed: Ann Brandewiede,
Circulation Manager.
WWW. jJPHARMTECHNOL.COM Novemser/Decemser 2006 w Vowtume 22 @ J PHARM TECHNOL 385